 PRINCETON, NJ ACCESSWIRE November 1, 2022 Sonnet BioTherapeutics Holdings, Inc. NASDAQ:SONN, a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the company will host a webcast to share initial clinical data from its SB101 clinical study with SON-1010 in oncology patients NCT05352750 and its SB102 clinical study with SON-1010 in healthy volunteers NCT05408572 on Wednesday, November 2, 2022 at 8:30 am ET. Webcast presenters will include:Richard Kenney, M.D. 